Copyright Reports & Markets. All rights reserved.

Global Targeted Drug ALK Inhibitors for NSCLC Market Status and Forecast 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Status and Forecast (2016-2027)
      • 1.3.2 Global Targeted Drug ALK Inhibitors for NSCLC Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Targeted Drug ALK Inhibitors for NSCLC Supply by Company

    • 2.1 Global Targeted Drug ALK Inhibitors for NSCLC Sales Value by Company
    • 2.2 Targeted Drug ALK Inhibitors for NSCLC Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Targeted Drug ALK Inhibitors for NSCLC Market Status by Type

    • 3.1 Targeted Drug ALK Inhibitors for NSCLC Type Introduction
      • 3.1.1 Crizotinib
      • 3.1.2 Ceritinib
      • 3.1.3 Alectinib
      • 3.1.4 Brigatinib
      • 3.1.5 Lorlatinib
      • 3.1.6 Other
    • 3.2 Global Targeted Drug ALK Inhibitors for NSCLC Market by Type
    • 3.3 North America: by Type
    • 3.4 Europe: by Type
    • 3.5 Asia Pacific: by Type
    • 3.6 Central & South America: by Type
    • 3.7 Middle East & Africa: by Type

    4 Global and Regional Targeted Drug ALK Inhibitors for NSCLC Market Status by Application

    • 4.1 Targeted Drug ALK Inhibitors for NSCLC Segment by Application
      • 4.1.1 Squamous Cell Carcinoma of NSCLC
      • 4.1.2 Adenocarcinoma of NSCLC
      • 4.1.3 Large Cell Carcinoma of NSCLC
    • 4.2 Global Targeted Drug ALK Inhibitors for NSCLC Market by Application
    • 4.3 North America: by Application
    • 4.4 Europe: by Application
    • 4.5 Asia Pacific: by Application
    • 4.6 Central & South America: by Application
    • 4.7 Middle East & Africa: by Application

    5 Global Targeted Drug ALK Inhibitors for NSCLC Market Status by Region

    • 5.1 Global Targeted Drug ALK Inhibitors for NSCLC Market by Region
    • 5.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Status
    • 5.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Status
    • 5.4 Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Status
    • 5.5 Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Status
    • 5.6 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Status

    6 North America Targeted Drug ALK Inhibitors for NSCLC Market Status

    • 6.1 North America Targeted Drug ALK Inhibitors for NSCLC Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Targeted Drug ALK Inhibitors for NSCLC Market Status

    • 7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Status

    • 8.1 Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Status

    • 9.1 Central & South America Targeted Drug ALK Inhibitors for NSCLC Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Status

    • 10.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Type and by Application

    • 12.1 Global Targeted Drug ALK Inhibitors for NSCLC Sales Value Forecast (2022-2027)
    • 12.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Type
    • 12.3 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Application

    13 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Region/Country

    • 13.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Pfizer
      • 14.1.1 Company Information
      • 14.1.2 Targeted Drug ALK Inhibitors for NSCLC Product Introduction
      • 14.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Novartis
      • 14.2.1 Company Information
      • 14.2.2 Targeted Drug ALK Inhibitors for NSCLC Product Introduction
      • 14.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Incepta Pharmaceuticals
      • 14.3.1 Company Information
      • 14.3.2 Targeted Drug ALK Inhibitors for NSCLC Product Introduction
      • 14.3.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Genvio Pharma Limited
      • 14.4.1 Company Information
      • 14.4.2 Targeted Drug ALK Inhibitors for NSCLC Product Introduction
      • 14.4.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Drug International Limted
      • 14.5.1 Company Information
      • 14.5.2 Targeted Drug ALK Inhibitors for NSCLC Product Introduction
      • 14.5.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Chugai Pharmaceutical (Hoffmann-La Roche group)
      • 14.6.1 Company Information
      • 14.6.2 Targeted Drug ALK Inhibitors for NSCLC Product Introduction
      • 14.6.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Beacon Pharma Limited
      • 14.7.1 Company Information
      • 14.7.2 Targeted Drug ALK Inhibitors for NSCLC Product Introduction
      • 14.7.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 ARIAD Pharmaceuticals (Takeda)
      • 14.8.1 Company Information
      • 14.8.2 Targeted Drug ALK Inhibitors for NSCLC Product Introduction
      • 14.8.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      This report provides a comprehensive analysis of current global Targeted Drug ALK Inhibitors for NSCLC market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Targeted Drug ALK Inhibitors for NSCLC industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

      According to this survey, the global Targeted Drug ALK Inhibitors for NSCLC market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

      Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Targeted Drug ALK Inhibitors for NSCLC Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Targeted Drug ALK Inhibitors for NSCLC market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

      The Global Targeted Drug ALK Inhibitors for NSCLC Market has been exhibited in detail in the following chapters
      Chapter 1 displays the basic product introduction and market overview.
      Chapter 2 provides the competition landscape of global Targeted Drug ALK Inhibitors for NSCLC industry.
      Chapter 3 provides the market analysis by type and by region
      Chapter 4 provides the market analysis by application and by region
      Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
      Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
      Chapter 12 provides the market forecast by type and by application
      Chapter 13 provides the market forecast by region
      Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
      Chapter 15 conclusions

      Segmented by Type
      Crizotinib
      Ceritinib
      Alectinib
      Brigatinib
      Lorlatinib
      Other

      Segmented by Application
      Squamous Cell Carcinoma of NSCLC
      Adenocarcinoma of NSCLC
      Large Cell Carcinoma of NSCLC

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Pfizer
      Novartis
      Incepta Pharmaceuticals
      Genvio Pharma Limited
      Drug International Limted
      Chugai Pharmaceutical (Hoffmann-La Roche group)
      Beacon Pharma Limited
      ARIAD Pharmaceuticals (Takeda)
      Buy now